Medspace Solutions Limited 07960162 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is Design and Installation of Specialist Medical Equipment. Digita Accounts Production Advanced 6.30.9574.0 true true false true 07960162 2024-04-01 2025-03-31 07960162 2025-03-31 07960162 bus:OrdinaryShareClass1 2025-03-31 07960162 core:CurrentFinancialInstruments 2025-03-31 07960162 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 07960162 core:Non-currentFinancialInstruments 2025-03-31 07960162 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 07960162 core:FurnitureFittingsToolsEquipment 2025-03-31 07960162 core:LandBuildings 2025-03-31 07960162 core:MotorVehicles 2025-03-31 07960162 core:OtherPropertyPlantEquipment 2025-03-31 07960162 bus:SmallEntities 2024-04-01 2025-03-31 07960162 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 07960162 bus:FilletedAccounts 2024-04-01 2025-03-31 07960162 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 07960162 bus:RegisteredOffice 2024-04-01 2025-03-31 07960162 bus:Director1 2024-04-01 2025-03-31 07960162 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 07960162 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 07960162 bus:Agent1 2024-04-01 2025-03-31 07960162 core:CommercialMotorVehicles 2024-04-01 2025-03-31 07960162 core:FurnitureFittings 2024-04-01 2025-03-31 07960162 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 07960162 core:LandBuildings 2024-04-01 2025-03-31 07960162 core:MotorVehicles 2024-04-01 2025-03-31 07960162 core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 07960162 core:PlantMachinery 2024-04-01 2025-03-31 07960162 core:Subsidiary1 2024-04-01 2025-03-31 07960162 core:Subsidiary1 2024-04-01 2025-03-31 07960162 core:Subsidiary1 1 2024-04-01 2025-03-31 07960162 core:Subsidiary1 countries:EnglandWales 2024-04-01 2025-03-31 07960162 countries:EnglandWales 2024-04-01 2025-03-31 07960162 2024-03-31 07960162 core:CostValuation 2024-03-31 07960162 core:FurnitureFittingsToolsEquipment 2024-03-31 07960162 core:LandBuildings 2024-03-31 07960162 core:MotorVehicles 2024-03-31 07960162 core:OtherPropertyPlantEquipment 2024-03-31 07960162 2023-04-01 2024-03-31 07960162 2024-03-31 07960162 bus:OrdinaryShareClass1 2024-03-31 07960162 core:CurrentFinancialInstruments 2024-03-31 07960162 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 07960162 core:Non-currentFinancialInstruments 2024-03-31 07960162 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 07960162 core:FurnitureFittingsToolsEquipment 2024-03-31 07960162 core:LandBuildings 2024-03-31 07960162 core:MotorVehicles 2024-03-31 07960162 core:OtherPropertyPlantEquipment 2024-03-31 07960162 core:AllSubsidiaries core:RenderingOrReceivingServices 2023-04-01 2024-03-31 07960162 core:OtherRelatedParties core:RenderingOrReceivingServices 2023-04-01 2024-03-31 07960162 core:Subsidiary1 1 2023-04-01 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07960162

Medspace Solutions Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

 

Medspace Solutions Limited

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3 to 4

Notes to the Unaudited Financial Statements

5 to 14

 

Medspace Solutions Limited

Company Information

Director

S M Wolf

Registered office

91A Church Lane
Bulphan
Upminster
RM14 3TR

Accountants

First Class Accounting Limited 91A Church Lane
Bulphan
Upminster
RM14 3TR

 

Chartered Accountants' Report to the Director on the Preparation of the Unaudited Statutory Accounts of
Medspace Solutions Limited
for the Year Ended 31 March 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Medspace Solutions Limited for the year ended 31 March 2025 as set out on pages 3 to 14 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Director of Medspace Solutions Limited in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Medspace Solutions Limited and state those matters that we have agreed to state to the Director of Medspace Solutions Limited in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Medspace Solutions Limited and its Director for our work or for this report.

It is your duty to ensure that Medspace Solutions Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Medspace Solutions Limited. You consider that Medspace Solutions Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Medspace Solutions Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

First Class Accounting Limited
91A Church Lane
Bulphan
Upminster
RM14 3TR

16 December 2025

 

Medspace Solutions Limited

(Registration number: 07960162)
Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

520,845

513,282

Investments

5

110,000

110,000

 

630,845

623,282

Current assets

 

Stocks

6

53,927

11,627

Debtors

7

1,142,465

1,050,458

Cash at bank and in hand

 

76,716

10,165

 

1,273,108

1,072,250

Creditors: Amounts falling due within one year

8

(949,562)

(641,726)

Net current assets

 

323,546

430,524

Total assets less current liabilities

 

954,391

1,053,806

Creditors: Amounts falling due after more than one year

8

(328,053)

(420,261)

Provisions for liabilities

(45,729)

(20,121)

Net assets

 

580,609

613,424

Capital and reserves

 

Called up share capital

9

200

200

Capital redemption reserve

100

100

Retained earnings

580,309

613,124

Shareholders' funds

 

580,609

613,424

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

 

Medspace Solutions Limited

(Registration number: 07960162)
Balance Sheet as at 31 March 2025

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 16 December 2025
 

.........................................
S M Wolf
Director

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
91A Church Lane
Bulphan
Upminster
RM14 3TR

These financial statements were authorised for issue by the director on 16 December 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures, fittings and equipment

20% to 50% straight line

Motor vehicles

33% straight line

Other tangible assets

20% to 33% straight line

Land and buildings

2% straight line

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 40 (2024 - 30).

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Other tangible assets
£

Total
£

Cost or valuation

At 1 April 2024

385,091

125,741

128,091

323,373

962,296

Additions

-

25,828

-

55,721

81,549

At 31 March 2025

385,091

151,569

128,091

379,094

1,043,845

Depreciation

At 1 April 2024

23,747

94,838

72,101

258,328

449,014

Charge for the year

7,702

13,414

21,396

31,474

73,986

At 31 March 2025

31,449

108,252

93,497

289,802

523,000

Carrying amount

At 31 March 2025

353,642

43,317

34,594

89,292

520,845

At 31 March 2024

361,344

30,903

55,990

65,045

513,282

Included within the net book value of land and buildings above is £353,642 (2024 - £361,344) in respect of freehold land and buildings.
 

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

5

Investments

2025
£

2024
£

Investments in subsidiaries

110,000

110,000

Subsidiaries

£

Cost or valuation

At 1 April 2024

110,000

Provision

Carrying amount

At 31 March 2025

110,000

At 31 March 2024

110,000

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

2025

2024

Subsidiary undertakings

HTQ Limited

Unit 7a Butts Pond Industrial Estate
Sturminster Newton
Dorset
DT10 1AZ

England and Wales

Ordinary

100%

100%

6

Stocks

2025
£

2024
£

Raw materials and consumables

53,927

11,627

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

7

Debtors

Current

Note

2025
£

2024
£

Trade debtors

 

889,715

873,454

Amounts owed by related parties

12

244,416

132,458

Other debtors

 

8,334

44,546

   

1,142,465

1,050,458

8

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

10

373,771

209,335

Trade creditors

 

597,825

393,484

Taxation and social security

 

(66,280)

(9,203)

Other creditors

 

44,246

48,110

 

949,562

641,726

Creditors include bank loans which are secured against the freehold property of the company of £12,617 (2024 - £14,841).

Creditors: amounts falling due after more than one year

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

10

328,053

420,261

Creditors include bank loans which are secured against the freehold property of the company of £214,046 (2024 - £224,440).

9

Share capital

Allotted, called up and fully paid shares

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

200

200

200

200

       

10

Loans and borrowings

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

328,053

420,261

Current loans and borrowings

2025
£

2024
£

Bank borrowings

25,741

36,773

Other borrowings

348,030

172,562

373,771

209,335

11

Dividends

2025

2024

£

£

Interim dividend of £1,122.00 (2024 - £1,132.00) per ordinary share

224,344

226,377

 

 

12

Related party transactions

Key management compensation

2025
£

2024
£

Salaries and other short term employee benefits

28,422

27,984

 

Medspace Solutions Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Director's remuneration

The director's remuneration for the year was as follows:

2025
£

2024
£

Remuneration

36,077

31,507

Summary of transactions with subsidiaries

HTQ Limited Management charges

Income and receivables from related parties

2025

2024

Subsidiary
£

Other related parties
£

Receipt of services

100,000

32,000